GFACX
Price
$65.04
Change
+$0.58 (+0.90%)
Updated
Dec 23 closing price
TGVFX
Price
$51.29
Change
+$0.58 (+1.14%)
Updated
Dec 20 closing price
Ad is loading...

GFACX vs TGVFX

Header iconGFACX vs TGVFX Comparison
Open Charts GFACX vs TGVFXBanner chart's image
American Funds Growth Fund of Amer C
Price$65.04
Change+$0.58 (+0.90%)
VolumeN/A
CapitalizationN/A
Touchstone Growth Opportunities A
Price$51.29
Change+$0.58 (+1.14%)
VolumeN/A
CapitalizationN/A
GFACX vs TGVFX Comparison Chart
Loading...
View a ticker or compare two or three
VS
GFACX vs. TGVFX commentary
Dec 24, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GFACX is a Buy and TGVFX is a Buy.

FUNDAMENTALS
Fundamentals
GFACX has more cash in the bank: 301B vs. TGVFX (172M). GFACX (0.00) and TGVFX (0.00) have matching dividends . GFACX was incepted earlier than TGVFX: GFACX (24 years) vs TGVFX (29 years). TGVFX is a more actively managed with annual turnover of: 55.00 vs. GFACX (31.00). GFACX has a lower initial minimum investment than TGVFX: GFACX (250) vs TGVFX (2500). TGVFX annual gain was more profitable for investors over the last year : 26.92 vs. GFACX (17.61). TGVFX return over 5 years is better than : 55.17 vs. GFACX (38.27).
GFACXTGVFXGFACX / TGVFX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence24 years29 years-
Gain YTD17.20026.61165%
Front LoadN/AN/A-
Min. Initial Investment250250010%
Min. Initial Investment IRAN/AN/A-
Net Assets301B172M175,000%
Annual Yield % from dividends0.000.00-
Returns for 1 year17.6126.9265%
Returns for 3 years-0.2625.06-1%
Returns for 5 years38.2755.1769%
Returns for 10 years58.7359.4199%
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
SYF65.451.18
+1.84%
Synchrony Financial
UAN74.211.00
+1.37%
CVR Partners LP
ASB23.990.29
+1.22%
Associated Banc-Corp
CMPX1.380.01
+0.73%
Compass Therapeutics
VRME0.63N/A
-0.11%
VerifyMe